Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.

Iván ChiviteLeire BerrocalElisa de LazzariSoodabeh NavadehCarla Lluis-GanellaAlexy InciarteLorena de la MoraAna González-CordónMaria Martínez-RebollarMontserrat LagunoBerta TorresJosé Luis BlancoEsteban MartinezJosep MallolasJuan Ambrosioni

Published in: The Journal of antimicrobial chemotherapy (2024)

Real-world studies demonstrate low discontinuation rates and high rates of virologic suppression in individuals treated with BIC/FTC/TAF, both TN and TE with and without previous detection of M184V substitution.

Keyphrases

antiretroviral therapy
hiv infected
hiv positive
human immunodeficiency virus
randomized controlled trial
hiv aids
hepatitis c virus
hiv testing
machine learning
men who have sex with men
loop mediated isothermal amplification
label free
case control